US · USD
REGN
Regeneron Pharmaceuticals Inc
- Day's range
- US$726.02 – US$777.43
- Day's volume
- US$765.5m
- 52-week range
- US$554.88 – US$852.03
Follow REGN on Fuolio
See how REGN weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountREGN in numbers
- Market cap
- US$69bn
- P/E
- 15.95
- P/B
- 2.18
- Dividend yield (12m)
- 0.50%
- Net debt/EBITDA
- -1.37
REGN trades at 15.95 times its earnings of the last 12 months.
REGN price history
REGN risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +13.31% | -4.89% | +15.91% |
| Volatility (annualised) | 36.73% | 33.34% | 29.71% |
| Largest drawdown | -21.23% | -58.50% | -58.50% |
| Positive months | 5/12 | 18/36 | 29/60 |
How much did investing in REGN return?
US$1,000.00 invested on 01/09/2021 would be worth US$1,264.79 today.
- Value today in REGN
- US$1,264.79
- Return over the period
- +26.48%
- Return per year
- +4.81%
- In the S&P 500
- US$1,776.31
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
REGN fundamentals
Valuation
- P/E15.95
- P/B2.18
- EV/EBITDA14.42
- EV/EBIT16.40
- EV/Revenue4.06
- P/EBIT17.96
- P/S4.44
- P/OCF14.75
- P/FCF—
- Earnings yield6.10%
- PEG ratio—
- Earnings per shareUS$46.07
- Book value per shareUS$337.52
Debt
- Net debt-US$6bn
- Net debt/EBITDA-1.37
- Net debt/Equity-0.19
- Debt/Equity0.06
- Current ratio3.34
- Quick ratio2.78
- Cash ratio1.45
Efficiency
- Gross margin—
- EBITDA margin28.14%
- Operating margin24.74%
- Net margin27.86%
- Asset turnover0.37
Profitability
- ROE13.65%
- ROA10.37%
- ROIC12.53%
- Payout8.03%
Growth
- Revenue CAGR (5 years)4.64%
- Earnings CAGR (5 years)-6.95%
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is REGN's fair price?
Two classic value formulas, with today's numbers. The current price is US$734.81.
- Graham's fair price
- US$591.50
- 19.50% below the price
√(22.50 × US$46.07 × US$337.52)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- US$58.67
- 92.02% below the price
US$3.52 (1-year average) ÷ 6%
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
REGN indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend yield | 0.46% | — | — | — | — | — | — | — |
| ROE | 14.41% | 15.03% | 15.22% | 19.14% | 43.03% | 31.86% | 19.08% | 27.91% |
| ROIC | 12.51% | 16.50% | 22.27% | 25.03% | 51.46% | 35.02% | 24.44% | 27.70% |
| Gross margin | — | — | — | — | — | — | 93.86% | 95.38% |
| EBITDA margin | 28.74% | 31.50% | 34.06% | 41.73% | 57.45% | 44.87% | 36.91% | 52.13% |
| Net margin | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% | 32.26% | 47.50% |
| Net debt/EBITDA | -1.61 | -1.57 | -1.98 | -1.13 | -0.40 | -0.42 | -1.33 | — |
REGN financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | US$14.3bn | US$14.2bn | US$13.1bn | US$12.2bn | US$16.1bn | US$8.5bn |
| Cost of sales | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| EBITDA | US$4.1bn | US$4.5bn | US$4.5bn | US$5.1bn | US$9.2bn | US$3.8bn |
| EBIT | US$3.6bn | US$4bn | US$4bn | US$4.7bn | US$8.9bn | US$3.6bn |
| Net finance result | US$1.7bn | US$789.2m | US$152.2m | US$119.9m | US$379m | US$233.8m |
| Profit before tax | US$5.2bn | US$4.8bn | US$4.2bn | US$4.9bn | US$9.3bn | US$3.8bn |
| Income tax | -US$725.8m | -US$367.3m | -US$245.7m | -US$520.4m | -US$1.3bn | -US$297.2m |
| Net income | US$4.5bn | US$4.4bn | US$4bn | US$4.3bn | US$8.1bn | US$3.5bn |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does REGN pay dividends?
Dividend yield per year
- 0.46%2025
- 0.38%2026
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Dividend | 17/08/2026 | 31/08/2026 | US$0.94 |
| Dividend | 19/05/2026 | 04/06/2026 | US$0.94 |
| Dividend | 19/02/2026 | 05/03/2026 | US$0.94 |
| Dividend | 19/11/2025 | 05/12/2025 | US$0.88 |
| Dividend | 15/08/2025 | 03/09/2025 | US$0.88 |
| Dividend | 19/05/2025 | 06/06/2025 | US$0.88 |
| Dividend | 19/02/2025 | 20/03/2025 | US$0.88 |
About Regeneron Pharmaceuticals
- Sector
- Manufacturing
Questions about REGN
How much is REGN today?
REGN is at US$734.81 (-3.09% on the day), last traded on 01/10/2026.
How much did REGN pay in dividends in 2025?
REGN paid US$3.52 per share in 2025, a dividend yield of 0.46%.
What are the P/E and P/B of REGN?
REGN trades at a P/E of 15.95 and a P/B of 2.18.
How much did REGN return in 12 months?
REGN returned 13.31% in 12 months, with annualised volatility of 36.73% and a largest drawdown of -21.23%.